FORM PTO-1449 TO BE FILED WITH INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 1259-064 Serial No. 09/035,708

Zemlan et al.

INFORMATION
DISCLOSURE STATEMEN

Applicant

DISCLOSURE STATEMENT BY APPLICANTS OF

March 5, 1998

643 1644

Filing Date

Group Art Unit

Examiner's name

JUN 2 4 133 TRADEMARK DES

U.S. PATENT DOCUMENTS

Examiner's	Document	Date	Name	Class/Sub-
Initial	Number			class
	None			

FOREIGN PATENT DOCUMENTS

Examiner's Initial,	Document Number	Date	Country/Name	Translation? yes/no
15CH	WO 93/03369	02/93	RCT) WO	N/A
	WO 93/08302	04/93	PCT WO	N/A
	WO 93/11231	06/93	PC/T WO	N/A
	WO 94/13795	06/94	Ρ¢ Τ ↓ <i>∪</i>	N/A
	WO 95/17429	06/95	PAT wo	N/A
Ψ	WO 96/04309	02/96	par wo	N/A

1/18/00

OTHER DOCUMENTS

retonel.

International Search Report for International Application No. PCT/US99/04955, mailed June 11, 1999.



FORM PTO-1449 TO BE FILED WITH INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No.1259-064 Serial No. 09/035,708

INFORMATION DISCLOSURE STATEMENT BY APPLICANTS Zemlan et al.
Applicant

· ·pp·····

March 5, 1998 Filing Date

Group Art Unit

) Jayes

Examiner's name

U.S. PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Name	Class/Sub- class
	5,601,985	02/97	Projanowski et al.	435/7.1
	5,492,812	02/96	Vooheis	435/7.1
77 0 -	5,486,460	01/96	Townsend	435/40.51
copier	5,262,332	11/93	Selkoe	436/518
COV	5,234,814	08/93	Card et al.	435/7.21
	5,200,324	04/06/93	Navaratnam et al.	435/20
	5,190,629	03/93	Sugihara et al.	204/182.8

FOREIGN PATENT DOCUMENTS

Examiner's	Document	Date	Country/Name	Translation?
Initial	Number			yes/no
	PCT/AU92/00610	11/91	AU	YES
(C)	PCT/BE91/00083	11/90	BE	NO
' -	PCT/EP92/02392	10/91	EP	YES
Colinar	PCT/EP95/03032	07/94	EP	YES
COA	PCT/GB91/00545	04/90	GB	YES
100	PCT/US92/06700	08/91	US	YES
Chonig to	PCT/US92/08470	10/92	V S	YES
	PCT/US93/09310	10/92	US	YES
	PCT/US94/08903	08/94	US	YES

No -	PCT/US94/13841	11/94	US	YES
~ non	PCT/US95/09445	36 795	US	YES
601	91120974.0	12/91	EP	YES
	93105149 4	03/93	EP	YES

OTHER DOCUMENTS

1. Roush, Science, 277 (July 1997) 31-32.

no copres

2. Roush, Science 267 (Feb. 1995) 793-794.

3. Faulkner, Lab Report, 18(7/8) July/August 53-59.

Examiner / Vayer	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The identification of any document herein is not intended to be, and should not be understood as being, an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given document may have a later effective date than at first seems apparent or the document may have an effective date which can be antedated. The "prior art" status of any document is a matter to be resolved during prosecution.



FORM PTO-1449 TO BE FILED WITH INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. <u>1259-064</u> Serial No. <u>09/035,708</u>		
	Zemlan et al.		
INFORMATION	Applicant		
DISCLOSURE STATEMENT		1643 /64H	
BY APPLICANTS	March 5, 1998	1643	
	Filing Date	Group Art Unit	
		RCN	
		Examiner's name	

U.S. PATENT DOCUMENTS

Examiner's	Document	Date	Name	Class/Sub-
Initial	Number			class
NO COM	-5 ,733,73 4	03/31/98	Trojanowski et al-	435/7:1

FOREIGN PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Country/Name	Translation? yes/no
	NONE			

OTHER DOCUMENTS

Rosengren et al., <u>Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF</u>, *J. of Neurochemistry* 67(5):2013-2018 (1996).

Adams et al., <u>Diffuse Axonal Injury in Head Injury: Definition, Diagnosis and Grading</u>, *Histopatholgy* 15:49-59 (1989).

3. Gotow and J. Tanaka, <u>Phosphorylation of Neurofilament H. Subunit as Related to Arrangement of Neurofilaments</u>, *J. Neuroscience Res.*, 37:691-713 (1994).

- 4. Binder et al., <u>The Distribution of Tau in the Mammalian Central Nervous System</u>, *Jeell Biology*, 101:1371-1378 (1985).
- 5. Greenberg et al., <u>Hydrofluoric Acid-treated τPHF Proteins Display the Same/Biochemical Propertities as Normal τ</u>, *J. of Biochemical Chem.*, 267(1):564-569 (1992).
- 6. Kosik and E. Finch, MAP2 and Tau Segregate into Dendritic and Axonal Domains After the Elabration of Morphologically Distinct Neurites: An Immunocytochemical Study of Cultured Rat Cerebrum, J. Neuroscience, 7(10):3142-3153 (1987).
- 7. Kosik et al., <u>Developmentally Regulated Expression of Specific Tau Sequences</u>, *Neuron* 2:1389-1397 (1989).
- 8. Litman et al., <u>Subcellular Localization of Tau mRNA in Differentiating Neuronal Cell Culture: Implications for Neuronal Polarity</u>, *Neuronf* 10:627-638 (1993).
- Wolozin et al., <u>A Neuronal Antigen in the Brains of Alzheimer Patients</u>, Science, 232:648-650.
- 10. Caputo et al., <u>Immunological Characterization of the Region of Tau Protein That is Bound to Alzheimer Paired Helical Filaments</u>, *Maurobiology of Aging*, 13:267-274 (1992).
- 11. Endoh et al., <u>Lack of Carboxyl Terminal Sequence of Tau in Ghost Tangles of Alzheimer's Disease</u>, *Brain Res.*, 601:164-170 (1993).
- 12. Carmel et al., <u>The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology</u>, *J. Biological Chem.*, 271(51):32789-32795 (1996).
- 13. Otvos et al., Monoclonal Antibody PHF-1 Recognizes Tau Protein Phosphorylated at Serine Residues 396 and 404, J. of Neuroscience Res., 39:669-673 (1994).
- 14. Zemlan and G. Dean, Monoclonal Antibody PHF-9 Recognizes Phosphorylated Serine 404 of Tau Protein and Lables Paired Helical Filaments, J. Neuroscience Res., 46:90-97.
- 15. Lee and S. Rook, Expression of Tau Protein in Non-neuronal Cells: Microbulule Binding and Stabilization, J. of Cell Sci., 102:227-237(1992).
- 16. Anderton et al., <u>Monoclonal Antibodies Show That Neurofibrillary Tangles and Neurofilaments Share Antigenic Determinants</u>, *Nature* 298:84-86 (1982).



- 17. Goedert et al., <u>Multiple Isoforms of Human Microtubule-Associated Protein Tau:</u>
 Sequences and Localization in Neurofibrillary Tangles of Alzheimer's Disease, Neuron, 3:519-526 (1989).
- 18. Arai et al., <u>Celebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology</u>, <u>Biochem</u>, and <u>Biophysical Res. Comm.</u>, 236:262-264 (1997).
- 19. Mori et al., <u>Tau in Ceberospinal Fluids: Establishment of the Sandwich ELISA with</u>
 Antibody Specific to the Repeat Sequence in Tau, Neurosci. Letters, 186:181-183 (1995).
- Johnson et al., <u>The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease</u>

 <u>Consists of Proteolytically Derived Fragments</u>, J. NeuroChemistry, 68(1):430-433 (1997).
 - 21. Munroe et al., <u>Tau Protein in Ceberospinal Fluid as an Aid in Diagnosis of Alzheimer's Disease</u>, Annals of Clinical and Lab. Sci., 25(3):207-217.
 - 22. Vigo-Pelfrey et al., <u>Elevation of Microtubule-associated Protein Tau in the Cerebrospinal Fluid of Patients With Alzheimer's Disease</u>, *Neurology*, 45:788-793 (1995).
 - 23. Lycke et al., Neurofilament Protein in Cerebrospinal Fluid: A Potential Marker of Activity in Multiple Sclerosis, Short Report (1997).
 - 24. Tullberg, et al., <u>CSF Neurofilament and Glial Fibrillary Acidic Protein in Normal Pressure Hydrocephalus</u>, *Neurology*, 50:1122-1127.
 - 25. Greenberg et al., <u>Hydrofluoric Acid-treated τPHF Proteins Display the Same Biochemical Properties as Normal τ*</u>, J. Biological Chem., 267(1):564-569.

Examiner ()	Date Considered	
T. / Vayer	1/18/00	

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The identification of any document herein is not intended to be, and should not be understood as being, an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given document may have a later effective date than at first seems apparent or the document may have an effective date which can be antedated. The "prior art" status of any document is a matter to be resolved during prosecution.

